Clover Biopharmaceuticals, a commercial-stage biotechnology company focused on innovative vaccine development, has announced the completion of first-participant enrollment in a Phase II clinical trial in Australia for its respiratory combination vaccine candidates SCB-1022 and SCB-1033.

The Phase II study is evaluating SCB-1022, a Respiratory Syncytial Virus (RSV) and Human Metapneumovirus (hMPV) combination vaccine, and SCB-1033, a triple-combination vaccine targeting RSV, hMPV and parainfluenza virus type 3 (PIV3). Both candidates are protein-based vaccines built on prefusion-stabilized F (PreF)-Trimer subunit antigens and utilise Clover’s validated Trimer-Tag vaccine technology platform.

Joshua Liang, Chief Executive Officer and Board Director of Clover Biopharmaceuticals, said,  “The initiation of the Phase II trial marks a key milestone in advancing the company’s first-in-class respiratory combination vaccine programme. He noted that the study builds on encouraging Phase I data, which suggested the potential for best-in-class RSV combination vaccines capable of re-vaccinating individuals who have previously received approved RSV vaccines, with the aim of restoring and broadening immune protection.”

The ongoing Phase II trial is a randomised, observer-blinded, multi-center study enrolling up to 420 older adults aged 60 to 85 years across Australia. Participants will be randomised to receive either SCB-1022, SCB-1033 or a placebo.

The primary objectives of the study are to assess the safety, reactogenicity and immunogenicity of the vaccine candidates. The trial is designed to support the development of combination respiratory vaccines that address multiple significant unmet medical needs, particularly in older populations at higher risk of severe respiratory infections.